Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Gettinger S. N.; Horn L.; Gandhi L.; Spigel D. R.; Antonia S. J.; Rizvi N. A.; Powderly J. D.; Heist R. S.; Carvajal R. D.; Jackman D. M.; Sequist L. V.; Smith D. C.; Leming P. D.; Topalian S. L.; Hodi F.; Sznol M.; Harbison C. T.; Kollia G. D.; Brahmer J. R.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

【24h】

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）在晚期非小细胞肺癌（NSCLC）患者中的长期生存，临床活性和安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2014年第5suppla期|共1页
作者
Gettinger S. N.; Horn L.; Gandhi L.; Spigel D. R.; Antonia S. J.; Rizvi N. A.; Powderly J. D.; Heist R. S.; Carvajal R. D.; Jackman D. M.; Sequist L. V.; Smith D. C.; Leming P. D.; Topalian S. L.; Hodi F.; Sznol M.; Harbison C. T.; Kollia G. D.; Brahmer J. R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) [J] . Gettinger S. N., Horn L., Gandhi L., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）在晚期非小细胞肺癌（NSCLC）患者中的长期生存，临床活性和安全性
2. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status [J] . Rizvi N. A., Shepherd F. A., Antonia S. J., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）一线单药治疗晚期非小细胞肺癌（NSCLC）：安全性，有效性以及与PD-L1状态相关的结果
3. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) [J] . Antonia S. J., Brahmer J. R., Gettinger S., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）与晚期非小细胞肺癌（NSCLC）的铂基双线化疗（PT-DC）联合使用
4. Does Sex Make a Difference in Survival of Patients Undergoing Resection for Early Stage Non-Small Cell Lung Cancer (NSCLC)? [C] . Steven J.Jubelirer, Nicole L.Varela, Christine A.Welch, 21st international conference on screening for lung cancer . 2009

机译：性别对早期非小细胞肺癌（NSCLC）切除患者的生存率有影响吗？
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. Nivolumab (anti-PD-1 BMS-936558 ONO-4538) in patients with advanced non-small cell lung cancer [O] . Arun Rajan, James L. Gulley 2014

机译：Nivolumab（anti-PD-1BMS-936558ONO-4538）用于晚期非小细胞肺癌患者
7. Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) [O] . S. Gettinger, L.Q. Chow, H. Borghaei, 2014

机译：Nivolumab的安全性和反应（抗PD-1; BMS-936558，ONO-4538）加上患者（PTS）中的Erlotinib，具有表皮生长因子受体突变体（EGFR MT）先进的非小细胞肺癌（NSCLC）

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅